Compare OPEN & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPEN | APGE |
|---|---|---|
| Founded | 2014 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.7B |
| IPO Year | 2020 | 2023 |
| Metric | OPEN | APGE |
|---|---|---|
| Price | $5.27 | $92.39 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $1.67 | ★ $109.67 |
| AVG Volume (30 Days) | ★ 26.4M | 1.0M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,371,000,000.00 | N/A |
| Revenue This Year | $3.04 | N/A |
| Revenue Next Year | $53.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.53 | $32.36 |
| 52 Week High | $10.87 | $90.69 |
| Indicator | OPEN | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 58.88 | 73.46 |
| Support Level | $5.24 | $73.06 |
| Resistance Level | $5.69 | N/A |
| Average True Range (ATR) | 0.30 | 3.31 |
| MACD | 0.08 | 0.71 |
| Stochastic Oscillator | 81.79 | 85.31 |
Opendoor Technologies Inc is an end-to-end real estate platform enabling customers to sell and buy a home online. Its product offerings include Sell to Opendoor, its core product where sellers sell their homes directly to the company, and it resells those homes to buyers; List with Opendoor, for customers to list their homes with a partner agent; and Opendoor Marketplace, a capital-light marketplace offering that connects home sellers with both institutional and retail buyers. In addition to these products, the company also offers its customers integrated title insurance and escrow services through its subsidiaries. A vast majority of the company's revenue is generated by its core product offering, where it acquires homes directly from sellers and resells those homes to buyers.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.